Print

ANDA Litigation Settlements

Case Name Drug Patent No(s). Publicly Available Terms

Jazz Pharms. Inc. v. Amneal Pharms. LLC, 13-0391 (D.N.J.)

Xyrem®
(sodium oxybate oral solution)

6,472,431
6,780,889
7,262,219
7,851,506
7,895,059
8,263,650
8,324,275

Ranbaxy, Sun, and Ohm Labs. stipulate that their respective ANDA products infringe the patents-in-suit. Ranbaxy, Sun and Ohm agree not to manufacture or to sell the generic drug during the life of the patents. The parties entered into a May 9 licensing agreement.

AstraZeneca Pharms. LP v. Teva Pharms. USA Inc., 14-1478 (D. Del.) Teva Pharms. USA Inc. v. AstraZeneca Pharms. LP, 15-0050 (D. Del.)

Byetta®
(exenatide)

6,858,576
6,872,700
6,956,026
7,297,761
6,902,744
7,521,423
7,741,269

Teva agrees not to market its generic product until October 15, 2017, or earlier if authorized by AstraZeneca.

The articles on our Website include some of the publications and papers authored by our attorneys, both before and after they joined our firm. The content of these articles should not be taken as legal advice.